Shaun P Brothers
Overview
Explore the profile of Shaun P Brothers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chee N, Carriere C, Miller Z, Welford S, Brothers S
Oncol Rep
. 2022 Nov;
49(1).
PMID: 36416348
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and difficult to treat cancers with tumors typically exhibiting high levels of chronic hypoxia. Hypoxia activates hypoxia-inducible factors (HIFs) that...
2.
Dennison J, Volmar C, Modarresi F, Ke D, Wang J, Gravel E, et al.
J Alzheimers Dis
. 2022 Jun;
88(1):385.
PMID: 35723129
No abstract available.
3.
Dennison J, Volmar C, Modarresi F, Ke D, Wang J, Gravel E, et al.
J Alzheimers Dis
. 2022 Jan;
86(1):173-190.
PMID: 35034905
Background: Alzheimer's disease (AD) has minimally effective treatments currently. High concentrations of resveratrol, a polyphenol antioxidant found in plants, have been reported to affect several AD-related and neuroprotective genes. To...
4.
Khalafi S, Zhu S, Khurana R, Lohse I, Giordano S, Corso S, et al.
Transl Oncol
. 2021 Nov;
15(1):101260.
PMID: 34735897
Gastric cancer (GC) is frequently characterized by resistance to standard chemotherapeutic regimens and poor clinical outcomes. We aimed to identify a novel therapeutic approach using drug sensitivity testing (DST) and...
5.
Kuznetsoff J, Owens D, Lopez A, Rodriguez D, Chee N, Kurtenbach S, et al.
Mol Cancer Res
. 2020 Oct;
19(2):215-222.
PMID: 33077485
Drug screens leading to successful targeted therapies in cancer have been mainly based on cell viability assays identifying inhibitors of dominantly acting oncogenes. In contrast, there has been little success...
6.
Lohse I, Brothers S
Anticancer Res
. 2020 Apr;
40(4):1789-1796.
PMID: 32234867
Pancreatic cancer is often diagnosed due to the patient seeking medical attention for abdominal pain. It is among the most painful cancers, with pain severity strongly correlating with prognosis. Perineural...
7.
Lohse I, Azzam D, Al-Ali H, Volmar C, Brothers S, Ince T, et al.
Anticancer Res
. 2019 Aug;
39(8):4023-4030.
PMID: 31366484
Background: Treatment options for patients with platinum-resistant ovarian cancer are generally palliative in nature and rarely have realistic potential to be curative. Because many patients with recurrent ovarian cancer receive...
8.
Mustafi S, Camarena V, Qureshi R, Yoon H, Volmar C, Huff T, et al.
EBioMedicine
. 2019 Apr;
43:201-210.
PMID: 30975544
Background: Bromodomain and extra-terminal inhibitors (BETi) have shown efficacy for the treatment of aggressive triple negative breast cancer (TNBC). However, BETi are plagued by a narrow therapeutic window as manifested...
9.
Chee N, Lohse I, Brothers S
Mol Cancer
. 2019 Mar;
18(1):49.
PMID: 30925920
Cells respond to hypoxia by shifting cellular processes from general housekeeping functions to activating specialized hypoxia-response pathways. Oxygen plays an important role in generating ATP to maintain a productive rate...
10.
Bagheri A, Habibzadeh P, Razavipour S, Volmar C, Chee N, Brothers S, et al.
Int J Mol Sci
. 2019 Mar;
20(5).
PMID: 30841499
Besides its key role in neural development, brain-derived neurotrophic factor (BDNF) is important for long-term potentiation and neurogenesis, which makes it a critical factor in learning and memory. Due to...